NCT05032066: A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis |
|
|
| Active, not recruiting | 2 | 153 | Europe, Canada, Japan, US, RoW | HZN-825, Placebo | Amgen | Idiopathic Pulmonary Fibrosis | 07/24 | 07/25 | | |
| Completed | 2 | 51 | US | Autoantibody Reductive Therapy, Treatment as Usual (TAU), Antibiotics and steroids | University of Alabama at Birmingham, National Heart, Lung, and Blood Institute (NHLBI), Brigham and Women's Hospital, Temple University, University of Pittsburgh | Idiopathic Pulmonary Fibrosis, Acute Fatal Form | 08/24 | 08/24 | | |
